APTOSE BIOSCIENCES INC (APS.CA) Stock Price, Forecast & Analysis
Canada - TSX:APS - CA03835T4081 - Common Stock
APS.CA Key Statistics, Chart & Performance
The current stock price of APS.CA is 2.36 CAD. In the past month the price increased by 38.82%. In the past year, price decreased by -70.86%.
APS.CA Latest News, Press Relases and Analysis
APS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 444.77M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 391.60M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 187.13M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 120.11M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 23.75 | 52.10M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.48M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 30.11M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.99M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.64M | ||
| MPH.CA | MEDICURE INC | N/A | 14.93M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.69M | ||
| TELO.CA | TELO GENOMICS CORP | N/A | 7.03M |
Related stock screener links
About APS.CA
Company Profile
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Company Info
APTOSE BIOSCIENCES INC
66 Wellington Street West, Suite 5300,, TD Bank Tower Box 48
TORONTO ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 13
Phone: 18589262730
APTOSE BIOSCIENCES INC / APS.CA FAQ
What does APTOSE BIOSCIENCES INC do?
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
What is the current price of APS stock?
The current stock price of APS.CA is 2.36 CAD. The price increased by 5.36% in the last trading session.
What is the dividend status of APTOSE BIOSCIENCES INC?
APS.CA does not pay a dividend.
What is the ChartMill rating of APTOSE BIOSCIENCES INC stock?
APS.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the ownership structure of APTOSE BIOSCIENCES INC (APS.CA)?
You can find the ownership structure of APTOSE BIOSCIENCES INC (APS.CA) on the Ownership tab.
APS.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to APS.CA. When comparing the yearly performance of all stocks, APS.CA is a bad performer in the overall market: 85.31% of all stocks are doing better.
APS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APS.CA. Both the profitability and financial health of APS.CA have multiple concerns.
APS.CA Financial Highlights
Over the last trailing twelve months APS.CA reported a non-GAAP Earnings per Share(EPS) of -66.26. The EPS increased by 79.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APS.CA Forecast & Estimates
7 analysts have analysed APS.CA and the average price target is 136.76 CAD. This implies a price increase of 5694.96% is expected in the next year compared to the current price of 2.36.